Revenue
2018
2019
2020
2021
2022
2023
2024
2025
EyePoint, Inc. (EYPT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 · Dec 31 | 2018 · Jun 30 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M | $34.4M | $20.4M | $4.6M | $3.0M | $7.5M | $1.6M | $26.6M | $3.5M | $2.1M | $3.5M | $5.0M | $23.1M |
| Research & development | $221.0M | $132.9M | $64.7M | $49.6M | $28.5M | $17.4M | $15.4M | $18.5M | $16.2M | $14.9M | $14.4M | $12.1M | $9.6M | $7.0M | $7.0M | $6.9M | $7.0M |
| Operating expenses | $274.8M | $189.1M | $121.1M | $141.0M | $92.2M | $71.7M | $68.2M | $43.6M | $29.2M | $26.1M | $23.4M | $20.1M | $17.0M | $14.2M | $28.7M | $15.0M | $14.0M |
| Operating income | −$243.4M | −$145.9M | −$75.1M | −$99.6M | −$55.3M | −$37.3M | −$47.9M | −$39.0M | −$26.3M | −$18.6M | −$21.8M | $6.4M | −$13.5M | −$12.0M | −$25.2M | −$10.0M | $9.1M |
| EBITDAderived | −$241.1M | −$144.3M | −$74.6M | −$97.2M | −$52.5M | −$34.6M | −$45.3M | — | −$25.1M | −$17.8M | −$20.9M | $7.3M | −$12.6M | −$11.0M | −$23.0M | −$6.6M | $12.4M |
| Net income | −$232.0M | −$130.9M | −$70.8M | −$102.3M | −$58.4M | −$45.4M | −$56.8M | −$86.1M | −$53.2M | −$18.5M | −$21.5M | $6.3M | −$13.4M | −$11.9M | −$24.8M | −$8.6M | $8.8M |
| Basic EPSper diluted share | -$3.17 | -$2.32 | -$1.82 | -$2.74 | -$2.03 | -$3.54 | -$5.44 | -$1.27 | -$1.15 | -$0.52 | -$0.68 | $0.22 | -$0.49 | -$0.52 | -$1.19 | -$0.44 | $0.48 |
| Diluted EPSper diluted share | -$3.17 | -$2.32 | -$1.82 | -$2.74 | -$2.03 | -$3.54 | -$5.44 | -$1.27 | -$1.15 | -$0.52 | -$0.68 | $0.21 | -$0.49 | -$0.52 | -$1.19 | -$0.44 | $0.46 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 17, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 2.4K | $15.00 | $36.6K | 0 |
| Mar 16, 2026Form 4 | Duker Jay S.President and CEO | BuyCommon Stock · indirect | 1.5K | $13.15 | $19.7K | 100.7K |
| Mar 4, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 2.4K | $17.87 | $43.6K | 0 |
| Feb 17, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 2.4K | $15.00 | $36.6K | 0 |
| Jan 5, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 42.5K | $17.10 | $727.5K | 0 |